ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 125

PD Signal Detected By Ultrasonography Relates to Joint Destruction in Rheumatoid Arthritis Under Biologics Therapy in Real World

Maasa Hama1, Yumiko Sugiyama1, Naomi Tsuchida1, Yosuke Kunishita1, Daiga Kishimoto1, Reikou Kamiyama1, Kaoru Minegishi-Takase1, Ryusuke Yoshimi1, Yohei Kirino2, Mitsuhiro Takeno3, Atsuhisa Ueda1 and Yoshiaki Ishigatsubo1, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologics, joint destruction, rheumatoid arthritis (RA) and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound

Session Type: Abstract Submissions (ACR)

Background/Purpose: Biologic DMARD (biologics) therapy for rheumatoid arthritis (RA) strongly suppresses joint destruction regardless of its efficacy for disease activity. On the contrary power Doppler (PD) signal detected by ultrasonography (US) is said to be the most potent predictive factor for subsequent radiologic progression. This study aimed to clarify whether PD signal predicts joint destruction of RA patients under biologics therapy in daily practice.

Methods: RA patients who began and continued to receive biologics for more than six months were included. Clinical, laboratory, and US examinations were conducted sequentially from baseline (1st) to the last observation (last). Bilateral wrists and all of the MCP and PIP joints were examined by PDUS and the PD signals were graded from 0 to 3 in each joint. The total PD score was defined as the sum of scores of individual joint, and mean score of several assessments during observational period was also calculated. Structural damage of hands at baseline and at the last was measured by using modified Sharp scoring method for hand X-ray (TSS). Patients having the change in TSS (delta TSS) exceeded 0.5 U per year were defined as showing radiologic progression.

Results: Objectives were 100 RA patients (female 85%, age 59.1±13.4 y.o., disease duration 8.0±8.2 years, 1st DAS28 4.84±1.43). Sixty-three patients continued the same drug (anti-TNF 31, tocilizumab 26, abatacept 6) whereas 37 patients switched biologics. During continuing biologics therapy for 25.3±16.8 months, structural damage progressed in 51% of the patients, who were classified into progressive group, including 18 patients with achieving clinical remission. The progressive group contained more patients who switched agents, and showed higher 1st DAS28 and higher last DAS28 as well as higher last total PD score, compared to the other group. Furthermore, yearly radiologic progression (delta TSS) weakly related to 1st, last, and mean total PD score in addition to 1st DAS28, 1st CRP, and 1st and last MMP-3. Multiple regression analysis using stepwise method revealed that both 1st CRP and mean total PD score were independently associated with joint destruction. For joint-based analysis of total 2200 joints, radiologic progression were seen in 155 joints (7.0%), of which wrists were mainly affected joints, and the existence of PD signal in a joint at any time during observational period was the potent risk for subsequent destruction of the joint (Table).

Conclusion: To practice ‘Treat to Target’ for achieving radiologic remission in real world, monitoring individual joint by PDUS will be helpful in carrying out optimal intervention even under biologics treatment.

 

n=2200

Progression

Non-progression

OR (95% CI)

P value

1st PD (+) joint, n (%)

74 (48.1%)

223 (10.9%)

7.81 (5.52, 11.1)

<0.0001

last PD (+) joint, n (%)

36 (24.8%)

83 (4.5%)

6.97 (4.51, 10.8)

<0.0001

mean PD (+) joint, n (%)

91 (59.1%)

282 (13.8%)

9.04 (6.40, 12.8)

<0.0001

 


Disclosure:

M. Hama,
None;

Y. Sugiyama,
None;

N. Tsuchida,
None;

Y. Kunishita,
None;

D. Kishimoto,
None;

R. Kamiyama,
None;

K. Minegishi-Takase,
None;

R. Yoshimi,
None;

Y. Kirino,
None;

M. Takeno,
None;

A. Ueda,
None;

Y. Ishigatsubo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pd-signal-detected-by-ultrasonography-relates-to-joint-destruction-in-rheumatoid-arthritis-under-biologics-therapy-in-real-world/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology